Perimenopause Symptoms Checklist: 34 Signs Women Should Track

Perimenopause symptoms extend far beyond hot flashes — the transition can involve more than 30 distinct hormonal, physical, and cognitive signs that fluctuate over months or years. This guide compiles an evidence-based perimenopause symptoms checklist drawn from the Study of Women's Health Across the Nation (SWAN), NAMS clinical position statements, and ACOG practice bulletins. You'll learn the prevalence of each symptom, how to track patterns clinicians look for, which signs warrant urgent evaluation, and how telehealth menopause care has expanded access to specialist consultation. Some brand mentions in this article link to our editorial reviews of telehealth providers.

Key facts at a glance

• Perimenopause averages 4 years but can last up to 10 years before the final menstrual period¹.
• Vasomotor symptoms affect 60-80% of women and persist a median of 7.4 years².
• The transition involves 30+ documented symptoms across 5 domains: vasomotor, genitourinary, psychological, musculoskeletal, and cognitive⁵.
• Tracking symptoms for 2-3 cycles helps rule out overlapping conditions like thyroid disease.

What perimenopause is — the short answer

Perimenopause is the hormonal transition leading to menopause, defined by the Stages of Reproductive Aging Workshop (STRAW+10) as the period beginning with menstrual cycle variability of 7 or more days and ending 12 months after the final menstrual period¹. Estradiol levels do not simply decline — they fluctuate erratically, often surging higher than premenopausal levels before dropping, which explains why perimenopause symptoms can feel more intense than postmenopausal symptoms⁵. The median age of perimenopause onset in U.S. women is 47, with a typical duration of 4 years, though SWAN cohort data document ranges from a few months to over a decade¹. Diagnosis is generally clinical, based on symptom pattern and menstrual history in women over 45⁴.

The 34-symptom perimenopause checklist by domain

Researchers and clinical bodies including NAMS and ACOG group perimenopause symptoms into five biologically distinct domains. The checklist below reflects symptoms documented in peer-reviewed cohort studies, with prevalence figures where available from SWAN and other longitudinal data⁵.

Vasomotor symptoms (60-80% prevalence)

1. Hot flashes — sudden heat sensation, 60-80% of women²
2. Night sweats — nocturnal vasomotor episodes, often disrupting sleep
3. Cold flashes — less common rebound chills following a hot flash
4. Heart palpitations — episodic, often co-occurring with hot flashes

Menstrual and reproductive changes

1. Cycle length variability — 7+ day change from baseline (STRAW marker)¹
2. Heavier bleeding (menorrhagia) — reported by approximately 25-30% of perimenopausal women⁵
3. Lighter or skipped periods
4. Increased PMS-like symptoms — breast tenderness, bloating
5. Mid-cycle spotting
6. Worsening menstrual migraines

Genitourinary syndrome of menopause (GSM, 27-84% prevalence)

1. Vaginal dryness — reported by 27-60% of perimenopausal women⁷
2. Painful intercourse (dyspareunia)
3. Vulvar itching or burning
4. Recurrent urinary tract infections
5. Urinary urgency / frequency
6. Stress incontinence
7. Reduced libido — prevalence 40-55%⁵

Psychological and mood symptoms

1. Depressed mood — perimenopausal women have a 2-4x increased risk of new-onset depression versus premenopause⁶
2. Anxiety / new-onset panic
3. Irritability
4. Mood swings
5. Emotional lability or tearfulness

Sleep disturbance

1. Insomnia — affecting 40-60% of perimenopausal women⁵
2. Early morning awakening
3. Non-restorative sleep

Cognitive symptoms

1. Brain fog — reported by approximately 60% of midlife women⁸
2. Word-finding difficulty
3. Short-term memory lapses
4. Reduced attention / concentration

Musculoskeletal and skin

1. Joint pain (arthralgia) — 50-60% prevalence in SWAN data⁵
2. Muscle aches
3. Hair thinning
4. Dry skin / itching
5. Weight redistribution to abdomen / increased visceral fat

How to use the checklist

Track each symptom daily for 2-3 cycles using either a paper diary or a validated app. Note severity (0-10), timing relative to menstrual day, and triggers (caffeine, alcohol, stress). NAMS recommends bringing this log to a clinical visit to support diagnosis and treatment discussions³.

Treatment options to discuss with a clinician

Management approaches for perimenopause symptoms vary by symptom severity, individual risk profile, and personal preference. Common evidence-based approaches discussed in NAMS and ACOG guidelines include:

• Menopausal hormone therapy (MHT) — typically transdermal estradiol (0.025-0.1 mg/day patch) with micronized progesterone (100-200 mg/day) for women with an intact uterus. NAMS' 2022 position statement supports MHT as first-line for moderate-to-severe vasomotor symptoms in women under 60 or within 10 years of menopause, after individual risk-benefit assessment³.
• Non-hormonal prescription options — low-dose paroxetine 7.5 mg (the only FDA-approved non-hormonal therapy for hot flashes), other SSRIs/SNRIs, gabapentin, oxybutynin, and the newer NK3-receptor antagonist fezolinetant (approved by the FDA in 2023 for moderate-to-severe vasomotor symptoms)³.
• Local vaginal estrogen — for genitourinary symptoms, typically estradiol cream, tablet, or ring; very low systemic absorption⁷.
• Cognitive behavioral therapy (CBT) — evidence-based for hot flash bother, insomnia, and mood symptoms⁵.
• Lifestyle modifications — regular aerobic and resistance exercise, sleep hygiene, dietary patterns lower in alcohol and refined carbohydrates, and stress reduction techniques⁵.

The appropriate combination depends on symptom severity, personal and family medical history (especially breast cancer, cardiovascular disease, VTE risk), and contraceptive needs. Treatment selection should be made with a clinician.

Telehealth provider options for perimenopause care

Several telehealth providers specialize in midlife women's hormonal health and may be useful for women seeking specialist-level evaluation without a long wait for an in-person menopause specialist. Examples of providers we have reviewed include:

• Midi Health accepts most commercial insurance plans and Medicare in many states, with clinicians who are NAMS-certified menopause practitioners; visits address vasomotor symptoms, GSM, mood, and bone health.
• Winona operates an async-first cash-pay model focused on bioidentical hormone therapy prescribing, with compounded and FDA-approved options.
• Alloy Women's Health provides asynchronous menopause care with menopause-trained clinicians and offers both FDA-approved hormone therapy and non-hormonal options.
• Evernow is a cash-pay menopause platform offering hormonal and non-hormonal prescriptions plus longitudinal clinician messaging.

Each provider differs in insurance acceptance, geographic availability, formulary, and care model. Reviewing each provider's documentation and discussing options with a clinician is the appropriate path to selection. See our brand reviews for full feature comparisons.

Safety: when to see a clinician promptly

Several scenarios in midlife women warrant urgent or non-routine evaluation rather than routine perimenopause management, per ACOG and NAMS guidance⁴:

• Heavy menstrual bleeding soaking through a pad or tampon every hour for 2 or more consecutive hours, or bleeding lasting more than 7 days — to evaluate for fibroids, polyps, or endometrial hyperplasia.
• Any bleeding after 12 months of amenorrhea (postmenopausal bleeding) — requires endometrial evaluation to rule out endometrial cancer.
• Severe pelvic pain or pain with bleeding.
• New severe headache, vision changes, or focal neurologic symptoms — particularly in women on hormone therapy.
• Calf pain or swelling, sudden shortness of breath, or chest pain — to evaluate for venous thromboembolism, especially in women on oral estrogen.
• Signs of premature ovarian insufficiency — menopausal symptoms before age 40 require specialist evaluation given bone and cardiovascular implications.
• Symptoms suggestive of thyroid disease, anemia, sleep apnea, or major depression — these can mimic or coexist with perimenopause and benefit from independent evaluation.

The NAMS 2022 position statement also notes contraindications to systemic hormone therapy include unexplained vaginal bleeding, active or recent breast cancer, active VTE, severe liver disease, and known thrombophilia³.

Cost and insurance considerations

Out-of-pocket costs for perimenopause care vary widely. In-person visits to a NAMS-certified specialist can range from $200-$500 per visit when uninsured, with limited availability in many regions. Telehealth menopause platforms generally fall into two categories: insurance-accepting (such as Midi Health, which bills most commercial plans, with patient cost typically the copay) and cash-pay (such as Winona and Evernow), where monthly subscription or visit fees commonly range from $35 to $150 per month, often inclusive of unlimited messaging.

Prescription medication costs depend on coverage. Generic transdermal estradiol patches can cost $15-$60/month with insurance and $40-$120/month without. Micronized progesterone (Prometrium and generics) typically costs $20-$50/month with insurance. Local vaginal estrogen products are often more expensive without coverage; the FDA-approved fezolinetant (Veozah) currently has limited insurance coverage and a list price of approximately $550/month⁵. Compounded bioidentical hormones are typically not covered by insurance and are not FDA-approved as a class. Coverage policies change frequently; verifying with the specific insurer and pharmacy is recommended.

Frequently asked questions

What are the first signs of perimenopause? The earliest perimenopause symptoms are typically changes in menstrual cycle length (shorter or longer than usual by 7+ days), heavier or lighter bleeding, new-onset PMS-like mood swings, and sleep disturbance. Hot flashes often appear later in the transition, per NAMS clinical guidance.

At what age does perimenopause start? Perimenopause typically begins between ages 40 and 44 in most women, with an average final menstrual period at age 51-52 in the United States. Earlier onset (before 40) is classified as premature ovarian insufficiency and warrants clinical evaluation, per ACOG.

How long do perimenopause symptoms last? The SWAN study found vasomotor symptoms persist for a median of 7.4 years, with some women experiencing them for more than a decade. The perimenopausal transition itself averages 4 years but can range from a few months to 10+ years.

Can you have perimenopause symptoms with regular periods? Yes. Early perimenopause is often defined by hormonal fluctuation, not cycle irregularity. Women with regular cycles can still experience hot flashes, sleep disruption, mood changes, and joint pain due to fluctuating estradiol and progesterone, per NAMS.

What perimenopause symptoms warrant seeing a doctor immediately? Heavy bleeding soaking a pad/tampon every hour for 2+ hours, bleeding after 12 months of amenorrhea, severe pelvic pain, or new neurological symptoms (vision changes, severe headache) require prompt evaluation to rule out fibroids, endometrial pathology, or other conditions.

Is hormone testing useful for diagnosing perimenopause? FSH and estradiol levels fluctuate widely during perimenopause, so a single blood test is often not diagnostic. NAMS and ACOG recommend diagnosis based on symptom pattern and menstrual history in women over 45, with hormone testing reserved for atypical presentations.

Sources

1. Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10. J Clin Endocrinol Metab. 2012;97(4):1159-1168. https://pubmed.ncbi.nlm.nih.gov/22344196/
2. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539. https://pubmed.ncbi.nlm.nih.gov/25686030/
3. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
4. ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216 (reaffirmed 2022). https://pubmed.ncbi.nlm.nih.gov/24463691/
5. Santoro N, Roeca C, Peters BA, Neal-Perry G. The Menopause Transition: Signs, Symptoms, and Management Options. J Clin Endocrinol Metab. 2021;106(1):1-15. https://pubmed.ncbi.nlm.nih.gov/33095879/
6. Bromberger JT, Kravitz HM. Mood and menopause: findings from SWAN. Obstet Gynecol Clin North Am. 2011;38(3):609-625. https://pubmed.ncbi.nlm.nih.gov/21961723/
7. Portman DJ, Gass ML. Genitourinary syndrome of menopause. Menopause. 2014;21(10):1063-1068. https://pubmed.ncbi.nlm.nih.gov/25160739/
8. Greendale GA, Karlamangla AS, Maki PM. The Menopause Transition and Cognition. JAMA. 2020;323(15):1495-1496. https://pubmed.ncbi.nlm.nih.gov/32282025/

Related brands & guides

• Midi Health review — insurance-accepting telehealth menopause care
• Winona review — cash-pay async hormone therapy platform
• Alloy Women's Health review — async menopause prescribing
• Evernow review — cash-pay menopause platform with longitudinal care

Updated May 29, 2026. Reviewed by Dr. Maya Chen, MD, NAMS-CMP.